chemXplore tracks 5 projects in Singapore, of which 3 are active.
Of the active ones, 3 new construction.
Self-contained platform uses real-time digital twins and AI agents to interpret equipment data, reduce false alarms, predict asset health and simulate energy savings across existing systems.
New facility combines perfumery, consumer testing and evaluation in recreated real-life settings; houses a Global Skin Cleansing Centre and will be joined by an Innovation Center in Q1 2027.
Seven-country Deco sale yields about $1bn net; EV/FY25 EBITDA multiple 21x; closing mid‑2027 (Indonesia late‑2026).
225,000 bbl/d oil capacity and 12 million m³/d gas processing; first of a six-platform series; P-80 and P-82 due to start production in 2027.
Low‑fouling RO elements ordered for a 50 million gallons-per-day wastewater reclamation plant in Changi, with completion targeted in 2028.
Dual Ang‑2/VEGF‑A inhibitor delivered vision gains, lesion regression and dosing intervals up to 20 weeks for most patients in a two‑year Asian PCV trial.
Two pre-salt platforms bound for the Búzios field will sail to Brazil for 2027 start-up; each can produce 225,000 b/d and treat 12 million m³/d of gas.
Partner will lead clinical development, manufacturing and global commercialization of AID351, an anti‑dengue antibody active across four serotypes; originators retain royalty and sublicence share.
Delivered low-oxygen MEG (<20 ppb) to an offshore platform via a 20-month ship-to-ship transfer from Singapore to Dampier using nitrogen purging and five sealed handling steps.
EBITDA +7.4% YoY to €391m and margin 16.1%; organic sales +3.2%; raw-material cost spike prompted pricing moves; FY‑26 EBITDA guidance slightly above last year at constant FX.
